Condition: AML, Adult · Sponsor: Shanghai Tong Ren Hospital
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.
This description comes directly from the study's public registry record.
Ligen Liu, MD · 18017337037 · llg3532@shtrhospital.com
Always discuss trial participation with your own doctor first.
| Changzhou Municipal No.1 People's Hospital | Changzhou, China | Not Yet Recruiting |
| Sichuan Provincial People's Hospital | Chengdu, China | Not Yet Recruiting |
| Jilin University China Japan Union Hospital | Ch’ang-ch’un, China | Not Yet Recruiting |
| Harbin Institute of Hematology and Oncology | Ha’erbin, China | Not Yet Recruiting |
| Anhui Provincial Hospital | Hefei, China | Not Yet Recruiting |
| the first hospital of Jiaxing affiliated hospital of Jiaxing University | Jiaxing, China | Not Yet Recruiting |
| Gansu Provincial People's Hospital | Lanzhou, China | Not Yet Recruiting |
| Lanzhou University NO.2 Hospital | Lanzhou, China | Not Yet Recruiting |
| Ningbo Medical Center Lihuili Huspital | Ningbo, China | Not Yet Recruiting |
| Shanghai Ruijin Hospital | Shanghai, China | Not Yet Recruiting |
| Shanghai Tong Ren hospital | Shanghai, China | Recruiting |
| The First Hospital of China Medical University | Shenyang, China | Not Yet Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05736965